Huahai Pharmaceutical announced that on July 31, 2026, it received a drug registration certificate from the National Medical Products Administration for telmisartan and hydrochlorothiazide tablets. The product contains 40 milligrams of telmisartan and 12.5 milligrams of hydrochlorothiazide per tablet, is classified as a chemical drug category 4, and is indicated for the treatment of essential hypertension. Huahai Pharmaceutical stated that this approval further enriches its product pipeline and helps enhance market competitiveness, but product manufacturing and sales are susceptible to uncertainties such as policy and market conditions, and investors are advised to be aware of the risks.
Zhejiang Huahai Pharmaceutical Co LtdReceived NMPA registration certificate for new drug, enriching pipeline and enhancing competitiveness.